ReviewInnere Medizin (Heidelberg, Germany)2026
[Treatment principles and long-term management of glomerulonephritides].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlomerulonephritides (GNs) are a heterogeneous group of mostly immune-mediated kidney diseases and are among of the most common causes of chronic renal failure, including end-stage renal disease. Advances in pathophysiology, histopathology, and immunotherapy have led to more differentiated therapeutic approaches. AIM OF THE STUDY: To present evidence-based treatment principles and concepts for long-term care in primary and secondary GNs, with particular reference to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. MATERIALS AND
methodsReview based on international guidelines (KDIGO), national guidelines, randomized controlled trials, meta-analyses, and current publications.
resultsThe treatment of glomerular diseases is based on a combination of supportive measures, disease-specific immunosuppression, and adjuvant therapy (e.g., lipid, anticoagulation, and vaccination management), as well as structured, long-term care. New pathogenesis-oriented therapies, in particular complement inhibitors and B cell-targeted strategies, are expanding the therapeutic spectrum and enabling low-steroid or steroid-free concepts. DISCUSSION: The long-term prognosis for GN patients depends largely on early diagnosis, correctly stratified initial therapy, consistently implemented supportive measures, close follow-up care, and lifelong nephrological care. Supportive measures are at least as relevant to prognosis as specific immunosuppression. Controversy exists in particular regarding the intensity, duration, and sequence of immunosuppressive therapy, as well as the cost-effectiveness of new biological and complement-targeted substances.
Indexed as
Identifiers
41945094What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.